The drug delivery devices market in India is expected to rise at a compound annual growth (CAGR) of 3.1% from $411m in 2016 to $510m by 2023, according to a report by GlobalData.
British scientists have worked out how many changes it takes to transform a healthy cell into a cancer.
To promote the adjustment of industrial structure and technological innovation in the drug and medical device sector, the Communist Party of China’s Central Committee and the State Council jointly released a guideline on the reform of the review and approval system, which came into effect on October 8, 2017.
In the age of e-commerce, there are multiple ways to develop potential client relationships online but site visits have been proven to be the most effective method. Nowadays, many forward-thinking companies are going global with great achievements but, in contrast to these early adopters, there are those companies who are still waiting on the sidelines, mostly due to a lack of expertise and experience. This is why Ddu has prepared a list of our tried and trusted methods for visiting and dealing with foreign clients.
The parliament of Australia’s second largest state passed legislation on Friday to allow terminally ill patients to seek medical help to end their lives, a bill that is expected to act as a catalyst for the rest of the country to adopt similar laws.
Synthetic gene circuits that only trigger powerful, tumor-specific immune responses when they detect certain disease markers may help immunotherapies to fight cancer more effectively, according to a new study.
New bone tissue grown from patients' own stem cells that attach themselves to an implanted, rigid lightweight plastic "scaffolding" which gradually degrades and is replaced as new bone grows, could soon be healing shattered limbs, according to a new research report.
Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained.
Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.